Invivogen
Menu

Anti-hPD-L1-mIgG1

Product Unit size Cat. code Docs. Price

Anti-hPD-L1-mIgG1

Human PD-L1 antibody - Mouse IgG1

Show product

100 µg

hpdl1-mab9

This antibody has been removed from our catalog. However, you may contact us if you wish to order minimal quantities.

Human PD-L1 mAb for murine studies

Anti-hPD-L1-mIgG1 features a variable region equivalent to that of Atezolizumab, a therapeutic monoclonal antibody (mAb) that targets PD-L1, blocking the interaction with its receptor PD-1. Atezolizumab (formerly known as MPDL3280A) is a fully-humanized IgG1 mAb with a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2]. It contains an N298A mutation that eliminates its ability to bind to human Fcγ receptors. In contrast to nivolumab, a therapeutic mAb that targets only human PD-1, Atezolizumab targets both human and mouse PD-L1. 

To enable studies in mice,  InvivoGen's Anti-hPD-L1-mIgG1 contains the constant region of mouse IgG1; an isotype exhibiting low CDC and no ADCC. Anti-hPD-L1-mIgG1 was generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G.

 

Anti-hPD-L1-mIgG1 InvivoFit™ is specifically designed for mouse studies:

  • Contains a mouse IgG1 Fc domain to prevent ADAs (anti-drug-antibodies)
  • Guaranteed sterile
  • Endotoxin level
  • Low aggregation, < 5%
  • No preservative
  • Binding validated by flow cytometry using EL4 cells expressing membrane-bound mouse PD-L1
 

The terms “Atezolizumab” and “MPDL3280A” are only used as references. Anti-hPD-L1-mIgG1 is not a pharmaceutical biosimilar of Atezolizumab. It has not been developed nor approved by Atezolizumab owner(s), and is not intended for any therapeutic or diagnostic use in humans or animals.

 

References:

1. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
2. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.

Back to the top

Specifications

Specificity: Targets cells expressing human and mouse PD-L1

Clonality: Monoclonal antibody

Isotype: Mouse IgG1, kappa

Source: CHO cells

Purification: Purified by affinity chromatography with protein G

Back to the top

Contents

  • 100 µg purified anti-hPD-L1-mIgG1 antibody, provided azide-free and lyophilized

 

room temperature Product is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

stability Lyophilized product is stable for at least 1 year

Back to the top
Customer Service
& Technical Support
Shopping cart is empty